Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

DiaTech Oncology Test Shows Positive Results

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Test identifies new therapeutic strategies for patients with lung cancer and ovarian cancer.

DiaTech Oncology has developed a predictive test that has been effective in clinical trials in helping oncologists determine the best chemotherapy treatment plans and therapeutic strategies for more than 50 types of cancers. The company has just published detailed results of the clinical trials for mesothelioma lung cancer, small-cell lung cancer (NSCLC) and advanced stage III and IV ovarian cancer at the American Society of Clinical Oncology (ASCO) conference held in Chicago.

The ASCO event, considered the world’s premiere oncology conference, features cutting-edge scientific presentations and attracts more than 25,000 oncology professionals yearly.

In previous clinical trials and published research, DiaTech Oncology’s predictive test – the MiCK® assay or Correct Chemo™ – showed an increase in complete or partial response rates, longer time to relapse and longer survival times for multiple types of cancer, including acute myeloid leukemia, lymphoma and non-Hodgkin lymphoma, and breast, bladder, ovarian, endometrial and lung cancers.

DiaTech has conducted extensive research on patients with ovarian cancer; however, the results published at ASCO were the first for advanced stage III and IV ovarian cancer or ovarian cancer patients who have relapsed and have resistance to one of the most commonly used chemotherapy drugs, carboplatin. Trial results showed that the MiCK assay can identify alternative chemotherapy treatments for ovarian cancer patients who have relapsing disease and carboplatin resistance.

Clinical results published at ASCO for mesothelioma are significantly notable because there are limited therapies currently available for this rare disease, which medical experts regard as one of the most aggressive and deadly of all cancers. The study was able to identify new chemotherapy strategies that could possibly help control mesothelioma in individual patients.

“DiaTech is the only test on the market that guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient,” says Cary Presant, M.D., DiaTech Chief Medical Officer. “Our clinical tests consistently reveal longer survival times and lower costs for chemotherapy cancer patients. We will carry on in our important work with our key institutional research partners. Our studies are yielding unexpected new leads for innovative therapeutic strategies.“

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos